November 17, 2022
1 min watch
Healio spoke with Brynn H. Parsegov, PA-C, about a presentation exploring the timing, as well as impact, of diagnosis for myeloproliferative neoplasms.
The presentation was given by Hans Hasselbalch, MD, PhD, a clinical researcher at University of Copenhagen’s Roskilde Hospital, at the 14th International Congress on Myeloproliferative Neoplasms.
“What I really took away from his presentation was just all of the ways that the inflammatory background of these diseases can have impacts on our patients,” Parsegov, physician assistant in the division of hematology and hematologic malignancies at University of Utah’s Huntsman Cancer Institute, said.
She noted that the field of myeloproliferative neoplasms is highly specialized but highlighted his emphasis on not “forgetting the whole picture” when treating patients.
“He, in his presentation, equated the inflammatory environment as being similar to a type II diabetes type environment, which we, in the general population, generally understand can be very, very harmful,” Parsegov said. “Looking at it with a more broad lens, in that way, will help me to provide more well-rounded care to my patients.”
- Hasselbalch H. A paradigm shift in the diagnosis and treatment of MPNs — sooner better than later? Presented at: 14th International Congress on Myeloproliferative Neoplasms; Oct. 27-28, 2022; Brooklyn, New York.